Compositions and methods for targeted delivery to cells
US-2024390271-A1 · Nov 28, 2024 · US
Drugs for prevention or treatment of sepsis
US12280070B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12280070-B2 |
| Application number | US-202418955967-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 21, 2024 |
| Priority date | Jun 28, 2023 |
| Publication date | Apr 22, 2025 |
| Grant date | Apr 22, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A drug for the prevention or treatment of sepsis is provided. The drug comprises an exosome containing a circRNA MOTOR, and a nucleotide sequence corresponding to the circRNA MOTOR is shown in SEQ ID NO: 1.
First claim
Opening claim text (preview).
What is claimed is: 1. A drug for the prevention or treatment of sepsis, wherein the drug comprises an exosome containing a circRNA MOTOR, wherein a nucleotide sequence corresponding to the circRNA MOTOR is shown in SEQ ID NO: 1. 2. The drug of claim 1 , wherein a dosage form of the drug is at least one of a tablet, a capsule, an oral liquid, a lozenge, an aerosol, an injection, an ointment, or a granule. 3. The drug of claim 2 , wherein the dosage form of the drug is the injection.
Assignees
Inventors
Classifications
Virus capsids or envelopes enclosing drugs (liposomes with additional exogenous lipids A61K9/127) · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Antibacterial agents · CPC title
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12280070B2 cover?
- A drug for the prevention or treatment of sepsis is provided. The drug comprises an exosome containing a circRNA MOTOR, and a nucleotide sequence corresponding to the circRNA MOTOR is shown in SEQ ID NO: 1.
- Who is the assignee on this patent?
- Univ Southeast
- What technology area does this patent fall under?
- Primary CPC classification A61K31/7105. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).